Breaking

Ukraine says Russia launched deadly aerial barrage as pressure grows on Kyiv to respond to US peace proposal
Pope Francis, voice for the poor who transformed the Catholic Church, dies at 88
This 1,000-mile river suffered decades of oil spills. Now it’s a legal person, things could change
Francis: The ‘outsider’ pope who faced fierce resistance to his reforms
What happens next after Francis’ death? How the Catholic Church will pick a successor
On Ecuador’s cocaine coast, with a fisherman who turned to smuggling
The Kremlin’s 30-hour truce was designed to shift blame to Ukraine. Did Trump buy it?
Meet the US cardinal now running the Vatican

Politics
World
Investing
Business
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

John Feneck: Gold Backdrop Looks “Amazing,” Plus 7 Stocks to Watch Now

Athena Gold Upsizes Flow-Through Private Placement, Announces Concurrent Hard Dollar Unit Offering

Finlay Minerals Enters into Earn-In Agreements with Freeport for its PIL & ATTY Properties

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,226)
- Investing (2,865)
- Politics (3,842)
- World (3,711)

Disclaimer: FinancesDataDriven.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest Posts

Copyright © 2025 financesdatadriven.com | All Rights Reserved

Top

Politics
World
Investing
Business

Type above and press Enter to search. Press Esc to cancel.